National Comprehensive Cancer Network Archives
Sep. 5, 2019— by Tom Wilemon Genetic testing for all metastatic breast cancer patients may be an optimal strategy for identifying additional patients with increased risk as well as response to targeted therapies, according to research published Aug. 29 in JAMA Oncology. In the study, 100 patients were tested regardless of whether they met the current National...
Jun. 22, 2017—Lauren Hackett, MPA, executive director of Administration and chief business officer for Vanderbilt-Ingram Cancer Center (VICC), has been elected to serve on the Finance Committee for the National Comprehensive Cancer Network (NCCN).
Mar. 30, 2017—Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer.